Champions of Cell and Gene Therapy – The Medicine Maker
How do we ensure that not only the rich benefit from cell and gene therapy? Rob Collison of Cambridge Consultants says: It’s about more than cutting costs
Digital biomarkers for patient-empowering connected health
The future promises a digitally connected healthcare system that empowers both patients and carers alike. So, what’s the next step for pharma companies and device developers with ambitions in the space?
In vitro diagnostics needs seismic change to improve patient outcomes and deliver economic benefits – Technology Network
The current state of in vitro diagnostics is no longer fit for purpose. Inadequate procedures mean that critical insights are often missed, while expenditure statistics on both sides of the Atlantic reveal lagging levels of investment.
CC and The Engine venture ecosystem: an alignment of ambition
We’re ramping up our commitment to The Engine, the ambitious venture ecosystem spun out of MIT to support ‘Tough Tech’ companies and solve key challenges in climate change, human health and advanced systems.
Getting the right distributed data architecture for you
To decentralise, or not to decentralise, that is the question. This Web3 dilemma reflects the likely thoughts of current digital leaders who want to make the best use of their digital assets while maintaining trust in their data systems.
Can cell therapy become cheaper and easier?
Cell and gene therapy is hailed as the future of 21st century medicine but is currently too expensive to be widely used. As a principal scientist in synthetic biology, Matthew Jones is part of a team addressing this issue in an ambitious project with exciting potential.